Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Common Equity: 2017-2025

Historic Common Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $120.1 million.

  • Aclaris Therapeutics' Common Equity fell 7.72% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 7.72%. This contributed to the annual value of $155.6 million for FY2024, which is 1.03% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Common Equity of $120.1 million as of Q3 2025, which was down 8.83% from $131.7 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Common Equity peaked at $235.8 million during Q2 2022, and registered a low of $112.3 million during Q1 2021.
  • Over the past 3 years, Aclaris Therapeutics' median Common Equity value was $144.1 million (recorded in 2025), while the average stood at $148.0 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Common Equity soared by 431.40% in 2021, and later declined by 28.89% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Common Equity (Quarterly) stood at $197.3 million in 2021, then increased by 0.14% to $197.6 million in 2022, then dropped by 20.46% to $157.2 million in 2023, then dropped by 1.03% to $155.6 million in 2024, then fell by 7.72% to $120.1 million in 2025.
  • Its Common Equity was $120.1 million in Q3 2025, compared to $131.7 million in Q2 2025 and $144.1 million in Q1 2025.